National Institutes of Health Chronic Graft-versus-Host Disease Staging in Severely Affected Patients: Organ and Global Scoring Correlate with Established Indicators of Disease Severity and Prognosis

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 632-639

  Baird, Kristin ^a   Steinberg, Seth M ^a   Grkovic, Lana ^a,b   Pulanic, Drazen ^a,b,h   Cowen, Edward W ^a   Mitchell, Sandra A ^a   Williams, Kirsten M ^a,c   Datiles, Manuel B ^d   Bishop, Rachel ^d   Bassim, Carol W ^e   Mays, Jacqueline W ^e   Edwards, Dean ^e   Cole, Kristen ^a   Avila, Daniele N ^a   Taylor, Tiffany ^a   Urban, Amanda ^a   Joe, Galen O ^f   Comis, Leora E ^f   Berger, Ann ^f   Stratton, Pamela ^g   Zhang, Dan ^a   Shelhamer, James H ^f   Gea Banacloche, Juan C ^a   Sportes, Claude ^a   Fowler, Daniel H ^a   Gress, Ronald E ^a   Pavletic, Steven Z ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b KBC Zagreb   (Croatia)

^c CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^d NATIONAL EYE INSTITUTE   (United States)

^e NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^h JOSIP JURAJ STROSSMAYER UNIVERSITY OF OSIJEK   (Croatia)

Author keywords

Chronic graft versus host disease; Consensus Criteria; Lung dysfunction; National Institutes of Health; Sclerotic skin; Stem cell transplant

Indexed keywords

ADULT; AGED; ARTICLE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; EOSINOPHIL COUNT; FEMALE; GRIP STRENGTH; HAZARD RATIO; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; LEE SYMPTOM SCALE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; SCORING SYSTEM; SHORT FORM 36; VALIDITY;

ADULT; CROSS-SECTIONAL STUDIES; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LONGITUDINAL STUDIES; LUNG; MALE; MIDDLE AGED; NATIONAL INSTITUTES OF HEALTH (U.S.); PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SEVERITY OF ILLNESS INDEX; SKIN; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; UNITED STATES;

EID: 84875554257     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.013     Document Type: Article

References (33)

1. Lee S.J., Vogelsang G., Flowers M.E. Chronic graft-versus-host disease. Biol Blood Marrow Transplant 2003, 9:215-233.
2. Carpenter P.A. Late effects of chronic graft-versus-host disease. Best Pract Res Clin Haematol 2008, 21:309-331.
3. Arora M., Klein J.P., Weisdorf D.J., et al. Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood 2011, 117:6714-6720.
4. Arora M., Nagaraj S., Witte J., et al. New classification of chronic GVHD: added clarity from the consensus diagnoses. Bone Marrow Transplant 2009, 43:149-153.
5. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
6. Shulman H.M., Kleiner D., Lee S.J., et al. Histopathologic diagnosis of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: II. Pathology Working Group report. Biol Blood Marrow Transplant 2006, 12:31-47.
7. Schultz K.R., Miklos D.B., Fowler D., et al. Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria For Clinical Trials in Chronic Graft-versus-Host Disease: III. Biomarker Working Group report. Biol Blood Marrow Transplant 2006, 12:126-137.
8. Pavletic S.Z., Martin P., Lee S.J., et al. Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant 2006, 12:252-266.
9. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: V. Ancillary Therapy and Supportive Care Working Group report. Biol Blood Marrow Transplant 2006, 12:375-396.
10. Martin P.J., Weisdorf D., Przepiorka D., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant 2006, 12:491-505.
11. Schubert M.M., Sullivan K.M., Morton T.H., et al. Oral manifestations of chronic graft-v-host disease. Arch Intern Med 1984, 144:1591-1595.
12. Lee S.J., Joffe S., Kim H.T., et al. Physicians' attitudes about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004, 104:2194-2200.
13. Ware J.E., Sherbourne C.D. The MOS 36-item Short-Form health survey (SF-36), I: conceptual framework and item selection. Med Care 1992, 30:473-483.
14. McQuellon R.P., Russell G.B., Cella D.F., et al. Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale. Bone Marrow Transplant 1997, 19:357-368.
15. Daughton D.M., Fix A.J., Kass I., et al. Maximum oxygen consumption and the ADAPT quality-of-life scale. Arch Phys Med Rehabil 1982, 63:620-622.
16. Grkovic L., Baird K., Steinberg S.M., et al. Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severity. Leukemia 2012, 26:633-643.
17. Mitchell S.A., Leidy N.K., Mooney K.H., et al. Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant 2010, 45:762-769.
18. Mehta C., Patel N.K. A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 1983, 78:427-434.
19. Hollander M., Wolfe D.A. Nonparametric Statistical Methods 1999, Wiley, New York, p. 189-269. 2nd ed.
20. Agresti A. Categorical Data Analysis 1990, Wiley, New York, p. 79-129.
21. Arai S., Jagasia M., Storer B., et al. Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria. Blood 2011, 118:4242-4249.
22. Kuzmina Z., Eder S., Bohm A., et al. Significantly worse survival of patients with NIH-defined chronic graft-versus-host disease and thrombocytopenia or progressive-onset type: results of a prospective study. Leukemia 2012, 26:746-756.
23. Pidala J., Kurland B., Chai X., et al. Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium. Blood 2011, 117:4651-4657.
24. Jacobsohn D.A., Kurland B.F., Pidala J., et al. Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood 2012, 120:2545-2552.
25. Hegarty A.M., Hodgson T.A., Lewsey J.D., et al. Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol 2002, 47:271-279.
26. Schiffman R.M., Christianson M.D., Jacobsen G., et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000, 118:615-621.
27. Williams K.M., Chien J.W., Gladwin M.T., et al. Bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation. JAMA 2009, 302:306-314.
28. McNeel D., Rubio M.T., Damaj G., et al. Hypereosinophilia as a presenting sign of acute graft-versus-host disease after allogeneic bone marrow transplantation. Transplantation 2002, 74:1797-1800.
29. Jacobsohn D.A., Schechter T., Seshadri R., et al. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation 2004, 77:1096-1100.
30. Aisa Y., Mori T., Nakazato T., et al. Blood eosinophilia as a marker of favorable outcome after allogeneic stem cell transplantation. Transpl Int 2007, 20:761-770.
31. Przepiorka D., Anderlini P., Saliba R., et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001, 98:1695-1700.
32. Kim D.H., Popradi G., Xu W., et al. Peripheral blood eosinophilia has a favorable prognostic impact on transplant outcomes after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:471-482.
33. Ahmad I., Labbe A.C., Chagnon M., et al. Incidence and prognostic value of eosinophilia in chronic graft-versus-host disease after nonmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011, 17:1673-1678.